Novel approaches to investigate one-carbon metabolism and related B-vitamins in blood pressure

Nutrients

Volumn 8, Issue 11, 2016, Pages

  McMahon, Amy ^a   McNulty, Helene ^a   Hughes, Catherine F ^a   Strain, J J ^a   Ward, Mary ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

ABPM; Blood pressure; DNA methylation; Hypertension; Methylenetetrahydrofolate reductase (MTHFR); Riboflavin

Indexed keywords

ACETYLSALICYLIC ACID; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FLAVINE ADENINE NUCLEOTIDE; HOMOCYSTEINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RIBOFLAVIN; VITAMIN B GROUP; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MTHFR PROTEIN, HUMAN; VITAMIN B COMPLEX;

ARTERIAL STIFFNESS; BLOOD PRESSURE MONITORING; CARBON METABOLISM; CARDIOVASCULAR DISEASE; CIRCADIAN RHYTHM; DNA METHYLATION; ENZYME ACTIVITY; GENETIC POLYMORPHISM; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HYPERTENSION; INTERVENTION STUDY; MEAN ARTERIAL PRESSURE; NONHUMAN; REPRODUCIBILITY; REVIEW; VITAMIN SUPPLEMENTATION; BLOOD PRESSURE; DRUG EFFECTS; METABOLISM; PHYSIOLOGY;

BLOOD PRESSURE; HUMANS; HYPERTENSION; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMORPHISM, GENETIC; VITAMIN B COMPLEX;

EID: 84995543055     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu8110720     Document Type: Review

References (143)

1. World Health Organisation—Global Health Observatory (GHO) Data for Raised Blood Pressure. Available online: http://www.who.int/gho/ncd/risk_factors/blood_pressure_prevalence:text/en/ (accessed on 19 September 2016).
2. Joffres, M., Falaschetti, E., Gillespie, C., Robitaille, C., Loustalot, F., Poulter, N., McAlister, F.A., Johansen, H., Baclic, O., Campbell, N. Hypertension prevalence, awareness, treatment and control in national surveys from England, the USA and Canada, and correlation with stroke and ischaemic heart disease mortality: A cross-sectional study. BMJ Open 2013, 3, e003423. [CrossRef] [PubMed]
3. Kearney, P.M., Whelton, M., Reynolds, K., Muntner, P., Whelton, P.K., He, J. Global burden of hypertension: Analysis of worldwide data. Lancet 2005, 365, 217-223. [CrossRef]
4. Mozaffarian, D., Benjamin, E.J., Go, A.S., Arnett, D.K., Blaha, M.J., Cushman, M., Das, S.R., de Ferranti, S., Després, J.-P., Fullerton, H.J., et al. Heart disease and stroke statistics-2016 update: A report from the american heart association. Circulation 2016, 133, e38-e360. [CrossRef] [PubMed]
5. Ettehad, D., Emdin, C.A., Kiran, A., Anderson, S.G., Callender, T., Emberson, J., Chalmers, J., Rodgers, A., Rahimi, K. Blood pressure lowering for prevention of cardiovascular disease and death: A systematic review and meta-analysis. Lancet 2016, 387, 957-967. [CrossRef]
6. Lewington, S., Clarke, R., Qizilbash, N., Peto, R., Collins, R. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360, 1903-1913. [CrossRef]
7. National Collaborating Centre for Chronic Conditions and the British Hypertension Society. Hypertension in Adults: Diagnosis and Management Management, Royal College of Physicians: London, UK, 2011.
8. Wright, J.T., Williamson, J.D., Whelton, P.S.K., Snyder, J.K., Sink, K.M., Rocco, M.V., Reboussin, D.C.E.M., Rahman, M., Oparil, S., Lewis, C.E., et al. A randomized trial of intensive versus standard blood-pressure control. N. Engl. J. Med. 2015, 373, 2103-2116. [PubMed]
9. Xie, X., Atkins, E., Lv, J., Bennett, A., Neal, B., Ninomiya, T., Woodward, M., MacMahon, S., Turnbull, F., Hillis, G.S., et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: Updated systematic review and meta-analysis. Lancet 2016, 387, 435-443. [CrossRef]
10. Williamson, J.D., Supiano, M.A., Applegate, W.B., Berlowitz, D.R., Campbell, R.C., Chertow, G.M., Fine, L.J., Haley, W.E., Hawfield, A.T., Ix, J.H., et al. Intensive vs. standard blood pressure control and cardiovascular disease outcomes in adults aged ≥ 75 years. JAMA 2016, 315, 2673-2682. [CrossRef] [PubMed]
11. Newton-Cheh, C., Johnson, T., Gateva, V., Tobin, M.D., Bochud, M., Coin, L., Najjar, S.S., Zhao, J.H., Heath, S.C., Eyheramendy, S.A. Genome-wide association study identifies eight loci associated with blood pressure. Nat. Genet. 2009, 41, 666-676. [CrossRef] [PubMed]
12. Levy, D., Ehret, G.B., Rice, K., Verwoert, G.C., Launer, L.J., Dehghan, A., Glazer, N.L., Morrison, A.C., Johnson, A.D., Aspelund, T. Genome-wide association study of blood pressure and hypertension. Nat. Genet. 2009, 41, 677-687. [CrossRef] [PubMed]
13. Ehret, G.B., Munroe, P.B., Rice, K.M., Bochud, M., Johnson, A.D., Chasman, D.I., Smith, A.V., Tobin, M.D., Verwoert, G.C., Hwang, S.-J., et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 2011, 478, 103-109. [CrossRef] [PubMed]
14. Flister, M.J., Tsaih, S.W., O’Meara, C.C., Endres, B., Hoffman, M.J., Geurts, A.M., Dwinell, M.R., Lazar, J., Jacob, H.J., Moreno, C. Identifying multiple causative genes at a single GWAS locus. Genome Res. 2013, 23, 1996-2002. [CrossRef] [PubMed]
15. Qian, X., Lu, Z., Tan, M., Liu, H., Lu, D. A meta-analysis of association between C677T polymorphism in the methylenetetrahydrofolate reductase gene and hypertension. Eur. J. Hum. Genet. 2007, 15, 1239-1245. [CrossRef] [PubMed]
16. Niu, W.-Q., You, Y.-G., Qi, Y. Strong association of methylenetetrahydrofolate reductase gene C677T polymorphism with hypertension and hypertension-in-pregnancy in Chinese: A meta-analysis. J. Hum. Hypertens. 2012, 26, 259-267. [CrossRef] [PubMed]
17. Wu, Y.L., Hu, C.Y., Lu, S.S., Gong, F.F., Feng, F., Qian, Z.Z., Ding, X.X., Yang, H.Y., Sun, Y.H. Association between methylenetetrahydrofolate reductase (MTHFR) C677T/A1298C polymorphisms and essential hypertension: A systematic review and meta-analysis. Metabolism 2014, 63, 1503-1511. [CrossRef] [PubMed]
18. Yang, B., Fan, S., Zhi, X., Li, Y., Liu, Y., Wang, D., He, M., Hou, Y., Zheng, Q., Sun, G. Associations of MTHFR gene polymorphisms with hypertension and hypertension in pregnancy: A meta-analysis from 114 studies with 15411 cases and 21970 controls. PLoS ONE 2014, 9, e87497. [CrossRef] [PubMed]
19. Yang, K.-M., Jia, J., Mao, L.-N., Men, C., Tang, K.-T., Li, Y.-Y., Ding, H.-X., Zhan, Y.-Y. Methylenetetrahydrofolate reductase C677T gene polymorphism and essential hypertension: A meta-analysis of 10,415 subjects. Biomed. Rep. 2014, 2, 699-708. [CrossRef] [PubMed]
20. Horigan, G., McNulty, H., Ward, M., Strain, J.J., Purvis, J., Scott, J.M. Riboflavin lowers blood pressure in cardiovascular disease patients homozygous for the 677C→T polymorphism in MTHFR. J. Hypertens. 2010, 28, 478-486. [CrossRef] [PubMed]
21. Wilson, C.P., Ward, M., McNulty, H., Strain, J.J., Trouton, T.G., Horigan, G., Purvis, J., Scott, J.M. Riboflavin offers a targeted strategy for managing hypertension in patients with the MTHFR 677TT genotype: A 4-y follow-up. Am. J. Clin. Nutr. 2012, 95, 766-772. [CrossRef] [PubMed]
22. Wilson, C.P., McNulty, H., Ward, M., Strain, J.J., Trouton, T.G., Hoeft, B.A., Weber, P., Roos, F.F., Horigan, G., McAnena, L., et al. Blood pressure in treated hypertensive individuals with the mthfr 677tt genotype is responsive to intervention with riboflavin: Findings of a targeted randomized trial. Hypertension 2013, 61, 1302-1308. [CrossRef] [PubMed]
23. Strain, J., Hughes, C.F., Mcnulty, H., Ward, M. Riboflavin Lowers Blood Pressure: A Review of a Novel Gene-nutrient Interaction. Nutr. Food Sci. Res. 2015, 2, 3-6.
24. Verdecchia, P., Porcellati, C., Schillaci, G., Borgioni, C., Ciucci, A., Battistelli, M., Guerrieri, M., Gatteschi, C., Zampi, I., Santucci, A., et al. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension (Dallas, TX, 1979) 1994, 24, 793-801. [CrossRef]
25. Hinman, A.T., Engel, B.T., Bickford, A.F. Portable blood pressure recorder Accuracy and preliminary use in evaluating intradaily variations in pressure. Am. Heart J. 1962, 63, 663-668. [CrossRef]
26. Bailey, L.B., Stover, P.J., Mcnulty, H., Fenech, M.F., Iii, J.F.G., Mills, J.L., Pfeiffer, C.M., Fazili, Z., Zhang, M., Ueland, P.M., et al. Biomarkers of Nutrition for Development—Folate Review. J. Nutr. 2015, 1-45. [CrossRef] [PubMed]
27. Kelly, P., McPartlin, J., Goggins, M., Weir, D.G., Scott, J.M. Unmetabolized folic acid in serum: Acute studies in subjects consuming fortified food and supplements. Am. J. Clin. Nutr. 1997, 65, 1790-1795. [PubMed]
28. Morris, M.S., Jacques, P.F., Rosenberg, I.H., Selhub, J. Circulating unmetabolized folic acid and 5-methyltetrahydrofolate in relation to anemia, macrocytosis, and cognitive test performance in American seniors. Am. J. Clin. Nutr. 2010, 91, 1733-1744. [CrossRef] [PubMed]
29. Russo, V., Martienssen, R., Riggs, A. Epigenetic mechanisms of gene regulation. Cold Spring Harb. Monogr. 1996, 13, 425-437.
30. Frosst, P., Blom, H.J., Milos, R., Goyette, P., Sheppard, C.A., Matthews, R.G., Boers, G.J., den Heijer, M., Kluijtmans, L.A., van den Heuvel, L.P. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 1995, 10, 111-113. [CrossRef] [PubMed]
31. Clarke, M., Ward, M., Strain, J.J., Hoey, L., Dickey, W., McNulty, H. B-vitamins and bone in health and disease: The current evidence. Proc. Nutr. Soc. 2014, 73, 330-339. [CrossRef] [PubMed]
32. McNulty, H., Strain, J.J., Pentieva, K., Ward, M. C1 metabolism and CVD outcomes in older adults. Proc. Nutr. Soc. 2012, 71, 213-221. [CrossRef] [PubMed]
33. Homocysteine Lowering Trialists. Dose-dependent effects of folic acid on blood concentrations of homocysteine: A meta-analysis of the randomized trials 1-3. Am. J. Clin. Nutr. 2005, 82, 806-812.
34. Tighe, P., Ward, M., Mcnulty, H., Finnegan, O., Dunne, A., Strain, J.J., Molloy, A.M., Duffy, M., Pentieva, K., et al. A dose-finding trial of the effect of long-term folic acid intervention: Implications for food fortification policy. Am. J. Clin. Nutr. 2011, 93, 11-18. [CrossRef] [PubMed]
35. Wald, D.S., Law, M., Morris, J.K. Homocysteine and cardiovascular disease: Evidence on causality from a meta-analysis. BMJ 2002, 325, 1202. [CrossRef] [PubMed]
36. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: A meta-analysis. JAMA 2002, 288, 2015-2022.
37. Wilson, C.P., McNulty, H., Scott, J.M., Strain, J.J., Ward, M. The MTHFR C677T polymorphism, B-vitamins and blood pressure. Proc. Nutr. Soc. 2010, 69, 156-165. [CrossRef] [PubMed]
38. The Heart Outcomes Prevention Evaluation Investigators (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N. Engl. J. Med. 2006, 354, 1567-1577.
39. Wang, X., Qin, X., Demirtas, H., Li, J., Mao, G., Huo, Y., Sun, N., Liu, L., Xu, X. Efficacy of folic acid supplementation in stroke prevention: A meta-analysis. Lancet 2007, 369, 1876-1882. [CrossRef]
40. Lee, M., Hong, K.-S., Chang, S.-C., Saver, J.L. Efficacy of homocysteine-lowering therapy with folic Acid in stroke prevention: A meta-analysis. Stroke 2010, 41, 1205-1212. [CrossRef] [PubMed]
41. Hankey, G.J., Eikelboom, J.W., Yi, Q., Lees, K.R., Chen, C., Xavier, D., Navarro, J.C., Ranawaka, U.K., Uddin, W., Ricci, S., et al. Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: A post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial. Lancet Neurol. 2012, 11, 512-520. [CrossRef]
42. Qin, X., Li, J., Spence, J.D., Zhang, Y., Li, Y., Wang, X., Wang, B., Sun, N., Chen, F., Guo, J., et al. Folic Acid Therapy Reduces the First Stroke Risk AssociatedWith Hypercholesterolemia Among Hypertensive Patients. Stroke 2016, 47, 2805-2812. [CrossRef] [PubMed]
43. Toole, J.F., Malinow, M.R., Chambless, L.E., Spence, J.D., Pettigrew, L.C., Howard, V.J., Sides, E.G., Wang, C.-H., Stampfer, M. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004, 291, 565-575. [CrossRef] [PubMed]
44. McMahon, J.A., Skeaff, C.M., Williams, S.M., Green, T.J. Lowering homocysteine with B vitamins has no effect on blood pressure in older adults. J. Nutr. 2007, 137, 1183-1187. [PubMed]
45. Van Dijk, R.A.J.M., Rauwerda, J.A., Steyn, M., Twisk, J.W.R., Stehouwer, C.D.A. Long-term homocysteinelowering treatment with folic acid plus pyridoxine is associated with decreased blood pressure but not with improved brachial artery endothelium-dependent vasodilation or carotid artery stiffness. Arterioscler. Thromb. Vasc. Biol. 2001, 21, 2072-2079. [CrossRef] [PubMed]
46. Mangoni, A.A., Sherwood, R.A., Swift, C.G., Jackson, S.H.D. Folic acid enhances endothelial function and reduces blood pressure in smokers: A randomized controlled trial. J. Intern. Med. 2002, 252, 497-503. [CrossRef] [PubMed]
47. Kennedy, B.P., Farag, N.H., Ziegler, A.G., Mills, P.J. Relationship of systolic blood pressure with plasma homocysteine: Importance of smoking status. J. Hypertens. 2003, 21, 1307-1312. [CrossRef] [PubMed]
48. Klerk, M., Verhoef, P., Clarke, R., Blom, H.J., Kok, F.J., Schouten, E.G., MTHFR Studies Collaboration Group. MTHFR 677C→T polymorphism and risk of coronary heart disease: A meta-analysis. JAMA 2002, 288, 2023-2031. [CrossRef] [PubMed]
49. Casas, J.P., Bautista, L.E., Smeeth, L., Sharma, P., Hingorani, A.D. Homocysteine and stroke: Evidence on a causal link from mendelian randomisation. Lancet 2005, 365, 224-232. [CrossRef]
50. Lewis, S.J., Ebrahim, S., Davey Smith, G. Meta-analysis of MTHFR 677C→T polymorphism and coronary heart disease: Does totality of evidence support causal role for homocysteine and preventive potential of folate? BMJ 2005, 331, 1053. [CrossRef] [PubMed]
51. Holmes, M.V., Newcombe, P., Hubacek, J.A., Sofat, R., Ricketts, S.L., Cooper, J., Breteler, M.M.B., Bautista, L.E., Sharma, P., Whittaker, J.C. Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: A meta-analysis of genetic studies and randomised trials. Lancet 2011, 378, 584-594. [CrossRef]
52. Clarke, R., Bennett, D.A., Parish, S., Verhoef, P., Dötsch-Klerk, M., Lathrop, M., Xu, P., Nordestgaard, B.G., Holm, H., Hopewell, J.C., et al. MTHFR Studies Collaborative Group Homocysteine and coronary heart disease: Meta-analysis of MTHFR case-control studies, avoiding publication bias. PLoS Med. 2012, 9, e1001177. [CrossRef] [PubMed]
53. McNulty, H., Dowey, L.R.C., Strain, J.J., Dunne, A., Ward, M., Molloy, A.M., McAnena, L.B., Hughes, J.P., Hannon-Fletcher, M., Scott, J.M. Riboflavin lowers homocysteine in individuals homozygous for the MTHFR 677C→T polymorphism. Circulation 2006, 113, 74-80. [CrossRef] [PubMed]
54. Reilly, R., Hopkins, S., Ward, M., McNulty, H., McCann, A., McNulty, B., Walton, J., Molloy, A., Strain, J.J., Flynn, A., et al. MTHFR 677TT genotype and related B-vitamins: Novel determinants of hypertension in healthy Irish adults. J. Inherit. Metab. Dis. 2013, 36, 35.
55. Wilcken, B., Bamforth, F., Li, Z., Zhu, H., Ritvanen, A., Renlund, M., Stoll, C., Alembik, Y., Dott, B., Czeizel, A.E., et al. Geographical and ethnic variation of the 677C>T allele of 5,10 methylenetetrahydrofolate reductase (MTHFR): Findings from over 7000 newborns from 16 areas world wide. J. Med. Genet. 2003, 40, 619-625. [CrossRef] [PubMed]
56. McAuley, E., McNulty, H., Hughes, C., Strain, J.J., Ward, M. Riboflavin status, MTHFR genotype and blood pressure: Current evidence and implications for personalised nutrition. Proc. Nutr. Soc. 2016, 75, 405-414. [CrossRef] [PubMed]
57. Guenther, B.D., Sheppard, C.A., Tran, P., Rozen, R., Matthews, R.G., Ludwig, M.L. The structure and properties of methylenetetrahydrofolate reductase from Escherichia coli suggest how folate ameliorates human hyperhomocysteinemia. Nat. Struct. Biol. 1999, 6, 359-365. [PubMed]
58. Yamada, K., Chen, Z., Rozen, R., Matthews, R.G. Effects of common polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductase. Proc. Natl. Acad. Sci. USA 2001, 98, 14853-14858. [CrossRef] [PubMed]
59. Bagley, P.J., Selhub, J. A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells. Proc. Natl. Acad. Sci. USA 1998, 95, 13217-13220. [CrossRef] [PubMed]
60. Shahzad, K., Hai, A., Ahmed, A., Kizilbash, N., Alruwaili, J. A structured-based model for the decreased activity of Ala222Val and Glu429Ala methylenetetrahydrofolate reductase (MTHFR) mutants. Bioinformation 2013, 9, 929-936. [CrossRef] [PubMed]
61. Antoniades, C., Shirodaria, C., Warrick, N., Cai, S., De Bono, J., Lee, J., Leeson, P., Neubauer, S., Ratnatunga, C., Pillai, R., et al. 5-Methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: Effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation 2006, 114, 1193-1201. [CrossRef] [PubMed]
62. Antoniades, C., Shirodaria, C., Leeson, P., Baarholm, O.A., Van-Assche, T., Cunnington, C., Pillai, R., Ratnatunga, C., Tousoulis, D., Stefanadis, C., et al. MTHFR 677C>T polymorphism reveals functional importance for 5-methyltetrahydrofolate, not homocysteine, in regulation of vascular redox state and endothelial function in human atherosclerosis. Circulation 2009, 119, 2507-2515. [CrossRef] [PubMed]
63. Crider, K.S., Yang, T.P., Berry, R.J., Bailey, L.B. Folate and DNA methylation: A review of molecular mechanisms and the evidence for folate’s role. Adv. Nutr. 2012, 3, 21-38. [CrossRef] [PubMed]
64. Haggarty, P., Hoad, G., Campbell, D.M., Horgan, G.W., Piyathilake, C., McNeill, G. Folate in pregnancy and imprinted gene and repeat element methylation in the offspring. Am. J. Clin. Nutr. 2013, 97, 94-99. [CrossRef] [PubMed]
65. Lévesque, N., Leclerc, D., Gayden, T., Lazaris, A., De Jay, N., Petrillo, S., Metrakos, P., Jabado, N., Rozen, R. Murine diet/tissue and human brain tumorigenesis alter Mthfr/MTHFR 5’-end methylation. Mamm. Genome 2016, 27, 122-134. [CrossRef] [PubMed]
66. Friso, S., Choi, S.-W., Girelli, D., Mason, J.B., Dolnikowski, G.G., Bagley, P.J., Olivieri, O., Jacques, P.F., Rosenberg, I.H., Corrocher, R., et al. A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc. Natl. Acad. Sci. USA 2002, 99, 5606-5611. [CrossRef] [PubMed]
67. Wang, L., Shangguan, S., Chang, S., Yu, X., Wang, Z., Lu, X., Wu, L., Zhang, T. Determining the association between methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and genomic DNA methylation level: A meta-analysis. Birth Defects Res. A Clin. Mol. Teratol. 2016, 106, 667-674. [CrossRef] [PubMed]
68. Lin, X., Lu, Q., Wang, T. Effect of MTHFR gene polymorphism impact on atherosclerosis via genome-wide methylation. Med. Sci. Monit. 2016, 22, 341-345. [CrossRef] [PubMed]
69. Ge, J., Wang, J., Zhang, F., Diao, B., Song, Z.F., Shan, L.L., Wang, W., Cao, H.J., Li, X.Q. Correlation between MTHFR gene methylation and pre-eclampsia, and its clinical significance. Genet. Mol. Res. 2015, 14, 8021-8028. [CrossRef] [PubMed]
70. Guarrera, S., Fiorito, G., Onland-Moret, N.C., Russo, A., Agnoli, C., Allione, A., Di Gaetano, C., Mattiello, A., Ricceri, F., Chiodini, P. Gene-specific DNA methylation profiles and LINE-1 hypomethylation are associated with myocardial infarction risk. Clin. Epigenet. 2015, 7, 133. [CrossRef] [PubMed]
71. Pusceddu, I., Herrmann, M., Kirsch, S.H., Werner, C., Hübner, U., Bodis, M., Laufs, U., Wagenpfeil, S., Geisel, J., Herrmann, W. Prospective study of telomere length and LINE-1 methylation in peripheral blood cells: The role of B vitamins supplementation. Eur. J. Nutr. 2016, 55, 1863-1873. [CrossRef] [PubMed]
72. Clement, D.L., De Buyzere, M.L., De Bacquer, D.A., de Leeuw, P.W., Duprez, D.A., Fagard, R.H., Gheeraert, P.J., Missault, L.H., Braun, J.J., Six, R.O., et al. Prognostic Value of Ambulatory Blood-Pressure Recordings in Patients with Treated Hypertension. N. Engl. J. Med. 2003, 348, 2407-2415. [CrossRef] [PubMed]
73. Hermida, R.C., Smolensky, M.H., Ayala, D.E., Portaluppi, F., Crespo, J.J., Fabbian, F., Haus, E., Manfredini, R., Mojón, A., Moyá, A., et al. 2013 Ambulatory blood pressure monitoring recommendations for the diagnosis of adult hypertension, assessment of cardiovascular and other hypertension-associated risk, and attainment of therapeutic goals. Chronobiol. Int. 2013, 30, 355-410. [CrossRef] [PubMed]
74. O’Brien, E., Parati, G., Stergiou, G., Asmar, R., Beilin, L., Bilo, G., Clement, D., de la Sierra, A., de Leeuw, P., Dolan, E., et al. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J. Hypertens. 2013, 31, 1731-1768. [CrossRef] [PubMed]
75. Solak, Y., Kario, K., Covic, A., Bertelsen, N., Afsar, B., Ozkok, A., Wiecek, A., Kanbay, M. Clinical value of ambulatory blood pressure: Is it time to recommend for all patients with hypertension? Clin. Exp. Nephrol. 2016, 20, 14-22. [CrossRef] [PubMed]
76. Dolan, E., Stanton, A.V., Thom, S., Caulfield, M., Atkins, N., McInnes, G., Collier, D., Dicker, P., O’Brien, E. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients—An Anglo-Scandinavian cardiac outcomes trial substudy. J. Hypertens. 2009, 27, 876-885. [CrossRef] [PubMed]
77. Dolan, E., Stanton, A., Thijs, L., Hinedi, K., Atkins, N., McClory, S., Den Hond, E., McCormack, P., Staessen, J.A., O’Brien, E. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: The Dublin outcome study. Hypertension 2005, 46, 156-161. [CrossRef] [PubMed]
78. Sesso, H.D., Stampfer, M.J., Rosner, B., Hennekens, C.H., Gaziano, J.M., Manson, J.E., Glynn, R.J. Systolic and Diastolic Blood Pressure, Pulse Pressure, and Mean Arterial Pressure as Predictors of Cardiovascular Disease Risk in Men. Hypertension 2000, 36, 801-807. [CrossRef] [PubMed]
79. Brown, D.W., Giles, W.H., Greenlund, K.J. Blood pressure parameters and risk of fatal stroke, NHANES II mortality study. Am. J. Hypertens. 2007, 20, 338-341. [CrossRef] [PubMed]
80. Verdecchia, P., Schillaci, G., Reboldi, G., Franklin, S.S., Porcellati, C. Different prognostic impact of 24-hour mean blood pressure and pulse pressure on stroke and coronary artery disease in essential hypertension. Circulation 2001, 103, 2579-2584. [CrossRef] [PubMed]
81. Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A.M., Kjeldsen, S.E., Laurent, S., et al. 2007 Guidelines for the management of arterial hypertension. Eur. Heart J. 2007, 28, 1462-1536. [CrossRef] [PubMed]
82. Morcet, J.F., Safar, M., Thomas, F., Guize, L., Benetos, A. Associations between heart rate and other risk factors in a large French population. J. Hypertens. 1999, 17, 1671-1676. [CrossRef] [PubMed]
83. Perret-Guillaume, C., Joly, L., Benetos, A. Heart rate as a risk factor for cardiovascular disease. Prog. Cardiovasc. Dis. 2009, 52, 6-10. [CrossRef] [PubMed]
84. Benetos, A., Rudnichi, A., Thomas, F., Safar, M., Guize, L. Influence of Heart Rate on Mortality in a French Population. Hypertension 1999, 33, 44-52. [CrossRef] [PubMed]
85. Reule, S., Drawz, P.E. Heart rate and blood pressure: Any possible implications for management of hypertension? Curr. Hypertens. Rep. 2012, 14, 478-484. [CrossRef] [PubMed]
86. Pickering, T.G., James, G.D., Boddie, C., Harshfield, G.A., Blank, S., Laragh, J.H. How common is white coat hypertension? JAMA 1988, 259, 225-228. [CrossRef] [PubMed]
87. Franklin, S.S., Thijs, L., Hansen, T.W., O’Brien, E., Staessen, J.A. White-coat hypertension: New insights from recent studies. Hypertension 2013, 62, 982-987. [CrossRef] [PubMed]
88. Mani, A. White-Coat Hypertension: A True Cardiovascular Risk? J. Clin. Hypertens. 2016, 18, 623-624. [CrossRef] [PubMed]
89. Pierdomenico, S.D., Cuccurullo, F. Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: An updated meta analysis. Am. J. Hypertens. 2011, 24, 52-58. [CrossRef] [PubMed]
90. Tientcheu, D., Ayers, C., Das, S.R., McGuire, D.K., de Lemos, J.A., Khera, A., Kaplan, N., Victor, R., Vongpatanasin, W. Target organ complications and cardiovascular events associated with masked hypertension and white-coat hypertension: Analysis from the dallas heart study. J. Am. Coll. Cardiol. 2015, 66, 2159-2169. [CrossRef] [PubMed]
91. Gustavsen, P.H., Høegholm, A., Bang, L.E., Kristensen, K.S. White coat hypertension is a cardiovascular risk factor: A 10-year follow-up study. J. Hum. Hypertens. 2003, 17, 811-817. [CrossRef] [PubMed]
92. Briasoulis, A., Androulakis, E., Palla, M., Papageorgiou, N., Tousoulis, D. White-coat hypertension and cardiovascular events: A meta-analysis. J. Hypertens. 2016, 34, 593-599. [CrossRef] [PubMed]
93. Wojciechowska, W., Stolarz-Skrzypek, K., Olszanecka, A., Klima, Ł., Gąsowski, J., Grodzicki, T., Kawecka-Jaszcz, K., Czarnecka, D. Subclinical arterial and cardiac damage in white-coat and masked hypertension. Blood Press. 2016, 25, 249-256. [CrossRef] [PubMed]
94. Scuteri, A., Morrell, C.H., Orru’, M., AlGhatrif, M., Saba, P.S., Terracciano, A., Ferreli, L.A.P., Loi, F., Marongiu, M., Pilia, M.G., et al. Gender specific profiles of white coat and masked hypertension impacts on arterial structure and function in the SardiNIA study. Int. J. Cardiol. 2016, 217, 92-98. [CrossRef] [PubMed]
95. Stevens, S.L., Wood, S., Koshiaris, C., Law, K., Glasziou, P., Stevens, R.J., McManus, R.J. Blood pressure variability and cardiovascular disease: Systematic review and meta-analysis. BMJ 2016, 354, i4098. [CrossRef] [PubMed]
96. Franklin, S.S., O’Brien, E., Thijs, L., Asayama, K., Staessen, J.A. Masked hypertension a phenomenon of measurement. Hypertension 2015, 65, 16-20. [CrossRef] [PubMed]
97. Lazaridis, A.A., Sarafidis, P.A., Ruilope, L.M. Ambulatory blood pressure monitoring in the diagnosis, prognosis, and management of resistant hypertension: Still a matter of our resistance? Curr. Hypertens. Rep. 2015, 17, 78. [CrossRef] [PubMed]
98. O’Brien, E., Sheridan, J., O’Malley, K. Dippers and non-dippers. Lancet 1988, 332, 397. [CrossRef]
99. Mezue, K., Isiguzo, G., Madu, C., Nwuruku, G., Rangaswami, J., Baugh, D., Madu, E. Nocturnal non-dipping blood pressure profile in black normotensives is associated with cardiac target organ damage. Ethn. Dis. 2016, 26, 279-284. [CrossRef] [PubMed]
100. Ohkubo, T., Hozawa, A., Yamaguchi, J., Kikuya, M., Ohmori, K., Michimata, M., Matsubara, M., Hashimoto, J., Hoshi, H., Araki, T., et al. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: The Ohasama study. J. Hypertens. 2002, 20, 2183-2189. [CrossRef] [PubMed]
101. Verdecchia, P., Angeli, F., Mazzotta, G., Garofoli, M., Ramundo, E., Gentile, G., Ambrosio, G., Reboldi, G. Day-night dip and early-morning surge in blood pressure in hypertension: Prognostic implications. Hypertension 2012, 60, 34-42. [CrossRef] [PubMed]
102. Fagard, R.H., Thijs, L., Staessen, J.A., Clement, D.L., De Buyzere, M.L., De Bacquer, D.A. Night-day blood pressure ratio and dipping pattern as predictors of death and cardiovascular events in hypertension. J. Hum. Hypertens. 2009, 23, 645-653. [CrossRef] [PubMed]
103. Eguchi, K., Hoshide, S., Ishikawa, J., Pickering, T.G., Schwartz, J.E., Shimada, K., Kario, K. Nocturnal nondipping of heart rate predicts cardiovascular events in hypertensive patients. J. Hypertens. 2009, 27, 2265-2270. [CrossRef] [PubMed]
104. Kario, K., Pickering, T.G., Matsuo, T., Hoshide, S., Schwartz, J.E., Shimada, K. Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. Hypertension 2001, 38, 852-857. [CrossRef] [PubMed]
105. Hermida, R.C., Ayala, D.E., Mojón, A., Fernández, J.R. Blunted sleep-time relative blood pressure decline increases cardiovascular risk independent of blood pressure level—The “normotensive non-dipper” paradox. Chronobiol. Int. 2013, 30, 87-98. [CrossRef] [PubMed]
106. Salles, G.F., Reboldi, G., Fagard, R.H., Cardoso, C.R.L., Pierdomenico, S.D., Verdecchia, P., Eguchi, K., Kario, K., Hoshide, S., Polonia, J., et al. Prognostic effect of the nocturnal blood pressure fall in hypertensive patients: The ambulatory blood pressure collaboration in patients with hypertension (ABC-H) meta-analysis. Hypertension 2016, 67, 693-700. [CrossRef] [PubMed]
107. Pierdomenico, S.D., Pierdomenico, A.M., Di Tommaso, R., Coccina, F., Di Carlo, S., Porreca, E., Cuccurullo, F. Morning blood pressure surge, dipping, and risk of coronary events in elderly treated hypertensive patients. Am. J. Hypertens. 2016, 29, 39-45. [CrossRef] [PubMed]
108. Xie, J.C., Yan, H., Zhao, Y.X., Liu, X.Y. Prognostic value of morning blood pressure surge in clinical events: A meta-analysis of longitudinal studies. J. Stroke Cerebrovasc. Dis. 2015, 24, 362-369. [CrossRef] [PubMed]
109. Hansen, T.W., Li, Y., Boggia, J., Thijs, L., Richart, T., Staessen, J.A. Predictive role of the nighttime blood pressure. Hypertension 2011, 57, 3-10. [CrossRef] [PubMed]
110. Grassi, G., Seravalle, G., Quarti-Trevano, F., Dell’Oro, R., Bombelli, M., Cuspidi, C., Facchetti, R., Bolla, G., Mancia, G. Adrenergic, metabolic, and reflex abnormalities in reverse and extreme dipper hypertensives. Hypertension 2008, 52, 925-931. [CrossRef] [PubMed]
111. Di Raimondo, D., Miceli, G., Casuccio, A., Tuttolomondo, A., Buttà, C., Zappulla, V., Schimmenti, C., Musiari, G., Pinto, A. Does sympathetic overactivation feature all hypertensives? Differences of sympathovagal balance according to night/day blood pressure ratio in patients with essential hypertension. Hypertens. Res. 2016, 39, 1-9. [CrossRef] [PubMed]
112. Kuo, T.B.J., Chen, C.-Y., Wang, Y.P., Lan, Y.-Y., Mak, K.-H., Lee, G.-S., Yang, C.C.H. The role of autonomic and baroreceptor reflex control in blood pressure dipping and nondipping in rats. J. Hypertens. 2014, 32, 806-816. [CrossRef] [PubMed]
113. Saeed, S., Wajea-Andreassen, U., Fromm, A., Øygarden, H., Naess, H., Gerdts, E. Blunted nightly blood pressure reduction is associated with increased arterial stiffness in ischemic stroke patients: A Norwegian stroke in the young study. J. Hypertens. 2015, 33, e41. [CrossRef] [PubMed]
114. Fontes-Guerra, P.C.A., Cardoso, C.R.L., Muxfeldt, E.S., Salles, G.F. Nitroglycerin-mediated, but not flow-mediated vasodilation, is associated with blunted nocturnal blood pressure fall in patients with resistant hypertension. J. Hypertens. 2015, 33, 1666-1675. [CrossRef] [PubMed]
115. Verdecchia, P., Angeli, F., Borgioni, C., Gattobigio, R., Reboldi, G. Ambulatory blood pressure and cardiovascular outcome in relation to perceived sleep deprivation. Hypertension 2007, 49, 777-783. [CrossRef] [PubMed]
116. Monte, M., Cambão, M., Mesquita Bastos, J., Polónia, J. Reproducibility of ambulatory blood pressure values and circadian blood pressure patterns in untreated subjects in a 1-11 month interval. Rev. Port. Cardiol. 2015, 34, 643-650. [CrossRef] [PubMed]
117. Keren, S., Leibowitz, A., Grossman, E., Sharabi, Y. Limited reproducibility of 24-h ambulatory blood pressure monitoring. Clin. Exp. Hypertens. 2015, 37, 599-603. [PubMed]
118. Hermida, R.C., Ayala, D.E., Fernández, J.R., Calvo, C. Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension. Hypertension 2008, 51, 69-76. [CrossRef] [PubMed]
119. Hermida, R.C., Ayala, D.E., Mojón, A., Fernández, J.R. Influence of circadian time of hypertension treatment on cardiovascular risk: Results of the MAPEC study. Chronobiol. Int. 2010, 27, 1629-1651. [CrossRef] [PubMed]
120. Gould, B.A., Mann, S., Davies, A.B., Altman, D.G., Raftery, E.B. Does placebo lower blood-pressure? Lancet 1981, 2, 1377-1381. [CrossRef]
121. Mancia, G., Omboni, S., Parati, G., Ravogli, A., Villani, A., Zanchetti, A. Lack of placebo effect on ambulatory blood pressure. Am. J. Hypertens. 1995, 8, 311-315. [CrossRef]
122. Kotsis, V., Stabouli, S., Bouldin, M., Low, A., Toumanidis, S., Zakopoulos, N. Impact of obesity on 24-hour ambulatory blood pressure and hypertension. Hypertension 2005, 45, 602-607. [CrossRef] [PubMed]
123. Cuspidi, C., Meani, S., Valerio, C., Negri, F., Sala, C., Maisaidi, M., Giudici, V., Zanchetti, A., Mancia, G. Body mass index, nocturnal fall in blood pressure and organ damage in untreated essential hypertensive patients. Blood Press. Monit. 2008, 13, 318-324. [CrossRef] [PubMed]
124. Demir, M., Günay, T., Özmen, G., Melek, M. Relationship between vitamin D deficiency and nondipper hypertension. Clin. Exp. Hypertens. 2013, 35, 45-49. [CrossRef] [PubMed]
125. Yilmaz, S., Sen, F., Ozeke, O., Temizhan, A., Topaloglu, S., Aras, D., Aydogdu, S. The relationship between vitamin D levels and nondipper hypertension. Blood Press. Monit. 2015, 20, 330-334. [CrossRef] [PubMed]
126. Kanbay, M., Isik, B., Akcay, A., Ozkara, A., Karakurt, F., Turgut, F., Alkan, R., Uz, E., Bavbek, N., Yigitoglu, R., et al. Relation between serum calcium, phosphate, parathyroid hormone and “nondipper” circadian blood pressure variability profile in patients with normal renal function. Am. J. Nephrol. 2007, 27, 516-521. [CrossRef] [PubMed]
127. Moore, T.J., Vollmer, W.M., Appel, L.J., Sacks, F.M., Svetkey, L.P., Vogt, T.M., Conlin, P.R., Simons-Morton, D.G., Carter-Edwards, L., Harsha, D.W. Effect of dietary patterns on ambulatory blood pressure: Results from the dietary approaches to stop hypertension (DASH) trial. DASH collaborative research group. Hypertension 1999, 34, 472-477. [CrossRef] [PubMed]
128. Miller, E.R., Erlinger, T.P., Young, D.R., Jehn, M., Charleston, J., Rhodes, D., Wasan, S.K., Appel, L.J. Results of the diet, exercise, and weight loss intervention trial (DEW-IT). Hypertension 2002, 40, 612-618. [CrossRef] [PubMed]
129. Paula, T.P., Viana, L.V., Neto, A.T.Z., Leitão, C.B., Gross, J.L., Azevedo, M.J. Effects of the DASH diet and walking on blood pressure in patients with type 2 diabetes and uncontrolled hypertension: A randomized controlled trial. J. Clin. Hypertens. 2015, 17, 895-901. [CrossRef] [PubMed]
130. Drouin-Chartier, J.-P., Gigleux, I., Tremblay, A.J., Poirier, L., Lamarche, B., Couture, P. Impact of dairy consumption on essential hypertension: A clinical study. Nutr. J. 2014, 13, 83. [CrossRef] [PubMed]
131. Machin, D.R., Park, W., Alkatan, M., Mouton, M., Tanaka, H. Hypotensive effects of solitary addition of conventional nonfat dairy products to the routine diet: A randomized controlled trial. Am. J. Clin. Nutr. 2014, 100, 80-87. [CrossRef] [PubMed]
132. Hobbs, D.A., Goulding, M.G., Nguyen, A., Malaver, T., Walker, C.F., George, T.W., Methven, L., Lovegrove, J.A. Acute ingestion of beetroot bread increases endothelium-independent vasodilation and lowers diastolic blood pressure in healthy men: A randomized controlled trial. J. Nutr. 2013, 143, 1399-1405. [CrossRef] [PubMed]
133. Jajja, A., Sutyarjoko, A., Lara, J., Rennie, K., Brandt, K., Qadir, O., Siervo, M. Beetroot supplementation lowers daily systolic blood pressure in older, overweight subjects. Nutr. Res. 2014, 34, 868-875. [CrossRef] [PubMed]
134. Kapil, V., Khambata, R.S., Robertson, A., Caulfield, M.J., Ahluwalia, A. Dietary nitrate provides sustained blood pressure lowering in hypertensive patients: A randomized, phase 2, double-blind, placebo-controlled study. Hypertension 2015, 65, 320-327. [CrossRef] [PubMed]
135. Coles, L.T., Clifton, P.M. Effect of beetroot juice on lowering blood pressure in free-living, disease-free adults: A randomized, placebo-controlled trial. Nutr. J. 2012, 11, 1-6. [CrossRef] [PubMed]
136. Larsen, T., Mose, F.H., Bech, J.N., Hansen, A.B., Pedersen, E.B. Effect of cholecalciferol supplementation during winter months in patients with hypertension: A randomized, placebo-controlled trial. Am. J. Hypertens. 2012, 25, 1215-1222. [CrossRef] [PubMed]
137. Pilz, S., Gaksch, M., Kienreich, K., Grübler, M., Verheyen, N., Fahrleitner-Pammer, A., Treiber, G., Drechsler, C., Ó Hartaigh, B., Obermayer-Pietsch, B., et al. Effects of vitamin D on blood pressure and cardiovascular risk factors: A randomized controlled trial. Hypertension 2015, 65, 1195-1201. [CrossRef] [PubMed]
138. Brüll, V., Burak, C., Stoffel-Wagner, B., Wolffram, S., Nickenig, G., Müller, C., Langguth, P., Alteheld, B., Fimmers, R., Naaf, S., et al. Effects of a quercetin-rich onion skin extract on 24 h ambulatory blood pressure and endothelial function in overweight-to-obese patients with (pre-)hypertension: A randomised double-blinded placebo-controlled cross-over trial. Br. J. Nutr. 2015, 14, 1263-1277. [CrossRef] [PubMed]
139. Sauder, K.A., McCrea, C.E., Ulbrecht, J.S., Kris-Etherton, P.M., West, S.G. Pistachio nut consumption modifies systemic hemodynamics, increases heart rate variability, and reduces ambulatory blood pressure in well-controlled type 2 diabetes: A randomized trial. J. Am. Heart Assoc. 2014, 3, 1-9. [CrossRef] [PubMed]
140. Appel, L.J., Moore, T.J., Obarzanek, E., Vollmer, W.M., Svetkey, L.P., Sacks, F.M., Bray, G.A., Vogt, T.M., Cutler, J.A., Windhauser, M.M., et al. A clinical trial of the effects of dietary patterns on blood pressure. N. Engl. J. Med. 1997, 336, 1117-1124. [CrossRef] [PubMed]
141. Cagnacci, A., Cannoletta, M., Xholli, A., Piacenti, I., Palma, F., Palmieri, B. Folate administration decreases oxidative status and blood pressure in postmenopausal women. Eur. J. Nutr. 2015, 54, 429-435. [CrossRef] [PubMed]
142. Cagnacci, A., Cannoletta, M., Volpe, A. High-dose short-term folate administration modifies ambulatory blood pressure in postmenopausal women. A placebo-controlled study. Eur. J. Clin. Nutr. 2009, 63, 1266-1268. [CrossRef] [PubMed]
143. Williams, C., Kingwell, B.A., Burke, K., McPherson, J., Dart, A.M. Folic acid supplementation for 3 weeks reduces pulse pressure and large artery stiffness independent of MTHFR genotype. Am. J. Clin. Nutr. 2005, 82, 26-31. [PubMed]